The potential effect of Schisandrin‐B combination with panitumumab in wild‐type and mutant colorectal cancer cell lines: Role of apoptosis and autophagy
- 19 February 2023
- journal article
- research article
- Published by Wiley in Journal of Biochemical and Molecular Toxicology
- Vol. 37 (5) , e23324
Abstract
Panitumumab is an approved monoclonal antibody for the treatment of colorectal cancer (CRC); however, mutations in EGFR signaling pathway resulted in poor response. Schisandrin‐B (Sch‐B) is a phytochemical that was suggested to protect against inflammation, oxidative stress, and cell proliferation. The present study aimed to investigate the potential effect of Sch‐B on panitumumab‐induced cytotoxicity in wild‐type Caco‐2, and mutant HCT‐116 and HT‐29 CRC cell lines, and the possible underlying mechanisms. CRC cell lines were treated with panitumumab, Sch‐B, and their combination. The cytotoxic effect of drugs was determined by MTT assay. The apoptotic potential was assessed in‐vitro by DNA fragmentation and caspase‐3 activity. Additionally, autophagy was investigated via microscopic detection of autophagosomes and quantitative reverse transcription‐polymerase chain reaction (qRT‐PCR) measurement of Beclin‐1, Rubicon, LC3‐II, and Bcl‐2 expression. The drug pair enhanced panitumumab cytotoxicity in all CRC cell lines where IC50 of panitumumab was decreased in Caco‐2 cell line. Apoptosis was induced through caspase‐3 activation, DNA fragmentation, and Bcl‐2 downregulation. Caco‐2 cell line treated with panitumumab showed stained acidic vesicular organelles, contrariwise, all cell lines treated with Sch‐B or the drug pair displayed green fluorescence indicating the lack of autophagosomes. qRT‐PCR revealed the downregulation of LC3‐II in all CRC cell lines, Rubicon in mutant cell lines, and Beclin‐1 in HT‐29 cell line only. Sch‐B at 6.5 µM promoted panitumumab‐induced apoptotic cell death, in‐vitro, via caspase‐3 activation and Bcl‐2 downregulation, rather than autophagic cell death. This novel combination therapy against CRC, allows the reduction of panitumumab dose to guard against its adverse effects.Keywords
This publication has 47 references indexed in Scilit:
- Aberrant Expression of Beclin-1 and LC3 Correlates with Poor Prognosis of Human Hypopharyngeal Squamous Cell CarcinomaPLOS ONE, 2013
- The crosstalk between autophagy and apoptosis: where does this lead?Protein & Cell, 2012
- Oncogenic B-RAF Signaling in Melanoma Impairs the Therapeutic Advantage of Autophagy InhibitionClinical Cancer Research, 2011
- Autophagy basicsMicrobiology and Immunology, 2010
- A flexible unified approach to the analysis of pre‐clinical combination studiesStatistics in Medicine, 2010
- Two Beclin 1-binding proteins, Atg14L and Rubicon, reciprocally regulate autophagy at different stagesNature Cell Biology, 2009
- Autophagy is associated with apoptosis in cisplatin injury to renal tubular epithelial cellsAmerican Journal of Physiology-Renal Physiology, 2008
- Analysis of recent pharmaceutical regulatory documents on analytical method validationJournal of Chromatography A, 2007
- Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibodyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2004
- Basic statistical methods for Analytical Chemistry. Part 2. Calibration and regression methods. A reviewThe Analyst, 1991